ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Sofinnova Partners announced on November 16 that it closed its Crossover II fund at €725 million, exceeding its original target. The Paris-based firm will invest in approximately 15 clinical-stage life sciences companies across Europe and select international markets to support their transition from clinical validation to commercialization.
Tap to vote and see what everyone thinks.
Summary by ByteBrief